Funding for this research was provided by:
Alexion Pharmaceuticals (N/A)
Received: 14 April 2020
Accepted: 26 November 2020
First Online: 6 January 2021
Change Date: 2 February 2021
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: The protocol was approved by the Institutional Review Board or Independent Ethics Committee at each participating center, and the study was conducted in accordance with the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines. Written informed consent was obtained from all individual participants or legal guardians, as applicable.
: Not applicable.
: Anja Gäckler: Honoraria and lecture fees from Alexion, Ablynx/Sanofi and Novartis.Ulf Schönermarck: study fees, travel support and consultancy fees from Alexion, and study fees and consultancy fees from Ablynx.Vladimir Dobronravov: no disclosures.Gaetano La Manna: no disclosures.Andrew Denker: employee of Alexion at the time of the study and owns stock in the company.Peng Liu: employee and shareholder of Alexion.Maria Vinogradova: no disclosures.Sung-Soo Yoon: no disclosures.Manuel Praga: personal fees from Otsuka, grants and personal fees from Alexion, personal fees from Retrophin.